A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

ClinicalTrials.gov ID: NCT05512390

Public ClinicalTrials.gov record NCT05512390. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 4, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Study identification

NCT ID: NCT05512390
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: AbbVie; Industry
Enrollment: 154 participants

Conditions and interventions

Conditions

Interventions

ABBV-319 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 25, 2023
Primary completion: Jan 31, 2027
Completion: Jan 31, 2027
Last update posted: Jan 15, 2026

2023 – 2027

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
University of Arizona Cancer Center - Tucson /ID# 247752	Tucson	Arizona	85724	Recruiting
Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232	Miami	Florida	33136	Completed
Allina Health System /ID# 251782	Minneapolis	Minnesota	55407-1321	Recruiting
University of Nebraska Medical Center /ID# 246715	Omaha	Nebraska	68198	Recruiting
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 249246	New York	New York	10065-6007	Recruiting
Novant Health Presbyterian Medical Center /ID# 246719	Charlotte	North Carolina	28204	Recruiting
Baylor Sammons Cancer Center /ID# 247715	Dallas	Texas	75246	Recruiting
University of Texas Health San Antonio MD Anderson Cancer Center /ID# 256234	San Antonio	Texas	78229	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05512390, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 15, 2026 · Synced May 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05512390 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →